Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2657 - Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab

Date

11 Sep 2017

Session

Poster display session

Presenters

Marcello Tiseo

Citation

Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390

Authors

M. Tiseo1, F. Facchinetti2, F. Gelsomino2, S. Buti1, M. Veneziani1, A. Squadrilli1, P. Bordi1, M. Bersanelli1, A. Cosenza1, L. Ferri1, E. Rapacchi1, G. Mazzaschi3, F. Leonardi1, F. Quaini3, A. Ardizzoni4, G. Missale5

Author affiliations

  • 1 Medical Oncology Unit, University Hospital of Parma, 43126 - Parma/IT
  • 2 Medical Oncology Unit, University Hospital of Parma, Parma/IT
  • 3 Department Of Medicine And Surgery, University Hospital of Parma, 43126 - Parma/IT
  • 4 Medical Oncology Unit, University Hospital Sant'Orsola, Bologna/IT
  • 5 Malattie Infettive Ed Epatologia, University Hospital of Parma, 43126 - Parma/IT
More

Resources

Abstract 2657

Background

Detection of predictive markers of anti-PD-1/PD-L1 antibodies activity is of pivotal interest in non-small cell lung cancer (NSCLC). This study aimed to identify a circulating immuno-profile as predictor of outcome in NSCLC patients treated with nivolumab.

Methods

A peripheral blood immuno-profile evaluation was performed at baseline (T0), after 2 (T1) and 4 cycles (T2) of bi-weekly nivolumab in advanced pre-treated NSCLC patients from two Italian Institutions. First tumor assessment was performed after 4 cycles and then every 2 months. FACS analysis of lymphocyte subpopulations [CD3, CD4, CD8, NK (CD56), Treg (FOXP3) and MDSC] was performed. Absolute and % changes of lymphocyte subsets together with their functional and proliferative activity were assessed. Quali-quantitative leucocyte composition at baseline and its variation during therapy were correlated with tumor response and survival.

Results

In the overall population of 54 treated patients, baseline Neutrophil-to-Lymphocyte ratio and NK count, lymphocyte count and CD4 variations during therapy showed a statistically significant prognostic role (p 

Conclusions

The number and function of NKs and the frequency of PD-1 expression in CD8+ cells could represent predictive peripheral immuno-biomarkers for nivolumab treatment in advanced NSCLC.

Clinical trial identification

NA

Legal entity responsible for the study

University Hospital of Parma

Funding

AIRC

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.